A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 31, 2010

Study Completion Date

November 30, 2011

Conditions
Cancer
Interventions
DRUG

CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection

10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks

DRUG

CNTO888 + gemcitabine

15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle

DRUG

CNTO888 + Paclitaxel and carboplatin

15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks

DRUG

CNTO888 + docetaxel

15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks

Trial Locations (5)

Unknown

Detroit

Tacoma

Barcelona

Madrid

PAU de Sanchinarro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY